Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$7.64

From 52W high−58.63%

Volume1.70M

Market cap$605.14M

P/E (TTM)—

P/S (TTM)2.5x

Div yield—

Key dataSep 18, 2026

Open

$7.64

From 52W high

−58.63%

Volume

1.70M

Market cap

$605.14M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−16.8x

P/E (TTM)

—

RSI (14)

32.9

MomentumView details →

1D Return

−3.48%

YTD Return

−54.67%

SummaryUpdated Jun 1, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey. The company went public in October 2019 and focuses on developing and commercializing novel treatments for gastrointestinal diseases. Phathom's primary asset is <b>VOQUEZNA</b> (vonoprazan), a potassium-competitive acid blocker that represents a new class of acid-suppressing medications for treating stomach acid-related conditions. The company has successfully launched VOQUEZNA in the United States and is working to expand its commercial footprint while developing additional indications for the drug.

Ask drillr about Phathom Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−16.8x

EV/Sales

2.5x

P/S (TTM)

2.5x

P/B (TTM)

−1.8x

ProfitabilityView details →

Gross Margin

82.92%

Net Margin

−41.34%

EBITDA Margin

−14.66%

ROE (TTM)

28.78%

ROA (TTM)

−30.29%

Asset Turnover

0.76x

GrowthView details →

Revenue YoY

+110.16%

EPS YoY

+72.94%

FCF YoY

+86.63%

Revenue CAGR 3Y

+1502.37%

EPS CAGR 3Y

+42.72%

EBITDA YoY

+86.31%

MomentumView details →

1D Return

−3.48%

YTD Return

−54.67%

1Y Return

−32.92%

RSI (14)

32.9

vs 50D SMA

−20.99%

vs 200D SMA

−36.12%

Capital & dividendView details →

Debt/Equity

−0.49x

Current Ratio

1.92x

Quick Ratio

1.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

−19.60%

Beats (12Q)

5/12

Next Q EPS Est

−$0.10

Avg Surprise (4Q)

−57.22%

Rev Surprise

−0.32%

Financials snapshotView financials →

Revenue (TTM)

239.66M

Net Income (TTM)

−99.07M

Op. CF (TTM)

−36.69M

Next earningsOct 29, 2026 →

Latest newsMore news →

SueWallSt notified investors of potential securities claims involving Phathom Pharmaceuticals, related to the company's full-year revenue guidance.51d ago

Similar companies

3D Medicines Inc.01244.HK Shattuck Labs, Inc.STTK CorMedix Inc.CRMD CytomX Therapeutics, Inc.CTMX AgomAb Therapeutics N.V. American Depositary SharesAGMB Bright Minds Biosciences Inc.DRUG Find similar companies →

Latest newsMore news →

Phathom Pharmaceuticals presented at the Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, highlighting rapid revenue growth and its first quarterly operating profit excluding stock-based compensation.11d ago SueWallSt notified investors of potential securities claims involving Phathom Pharmaceuticals, related to the company's full-year revenue guidance.51d ago